Sacral Nerve Stimulation (SNS) Devices

Sacral Nerve Stimulation (SNS) Devices

Global Sacral Nerve Stimulation (SNS) Devices Market to Reach US$2.5 Billion by 2030

The global market for Sacral Nerve Stimulation (SNS) Devices estimated at US$1.2 Billion in the year 2023, is expected to reach US$2.5 Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2023-2030. Implantable SNS Devices, one of the segments analyzed in the report, is expected to record a 11.0% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the External SNS Devices segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$325.3 Million While China is Forecast to Grow at 14.3% CAGR

The Sacral Nerve Stimulation (SNS) Devices market in the U.S. is estimated at US$325.3 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$558.2 Million by the year 2030 trailing a CAGR of 14.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.9% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Sacral Nerve Stimulation (SNS) Devices Market - Key Trends and Drivers Summarized

How Are SNS Devices Revolutionizing the Treatment of Pelvic Floor Disorders?
Sacral Nerve Stimulation (SNS) devices are emerging as a game-changer in the treatment of pelvic floor disorders, such as urinary and fecal incontinence, by providing a minimally invasive, neuromodulation-based approach. These devices work by sending mild electrical pulses to the sacral nerves, which control the bladder, bowel, and pelvic floor muscles, helping to restore normal function and improve patient quality of life. SNS therapy is gaining traction as an effective alternative to more invasive surgical options, particularly among patients who do not respond well to conservative treatments like medications or behavioral therapy. The growing prevalence of incontinence, especially among the aging population and those with underlying neurological conditions, is driving demand for SNS devices in healthcare settings. The efficacy, safety, and minimally invasive nature of SNS therapy are making it an increasingly popular choice among urologists, colorectal surgeons, and gynecologists, leading to the widespread adoption of these devices in clinical practice.

What Technological Innovations Are Enhancing the Effectiveness of SNS Devices?
Technological advancements in neuromodulation and medical device design are significantly enhancing the effectiveness, safety, and patient experience of SNS devices. Modern SNS devices are now available with rechargeable batteries, MRI compatibility, and wireless programming capabilities, which improve device longevity, reduce the need for frequent replacements, and provide greater convenience for both patients and healthcare providers. The development of smaller, more discreet implantable devices with improved lead designs is minimizing surgical complexity and recovery time, enhancing patient comfort and satisfaction. Furthermore, the integration of Bluetooth and remote monitoring technologies in SNS devices allows for better management of therapy settings and remote patient care, enabling clinicians to optimize treatment outcomes. These technological innovations are expanding the applications of SNS devices and driving their adoption in the management of pelvic floor disorders.

What Market Trends Are Shaping the Future of SNS Devices?
The SNS devices market is shaped by several key trends, including the rising adoption of minimally invasive treatments, increasing awareness of pelvic health disorders, and the expansion of healthcare infrastructure in emerging markets. As more patients and healthcare professionals recognize the benefits of minimally invasive treatments over conventional surgical interventions, the demand for SNS devices is growing rapidly. The increasing awareness of pelvic floor disorders, supported by educational campaigns and growing healthcare access, is driving more patients to seek effective treatments like SNS. The expansion of healthcare infrastructure, particularly in developing regions, is creating new opportunities for SNS device manufacturers to tap into underserved markets. Additionally, the focus on expanding indications for SNS therapy beyond incontinence, such as chronic pelvic pain and constipation, is opening new avenues for market growth.

What Are the Key Drivers of Growth in the Sacral Nerve Stimulation (SNS) Devices Market?
The growth in the Sacral Nerve Stimulation (SNS) devices market is driven by several factors, including advancements in device technology, increasing prevalence of pelvic floor disorders, and the rising demand for minimally invasive treatment options. The development of rechargeable, MRI-compatible, and remote-controlled SNS devices is enhancing their appeal among both patients and healthcare providers. The aging population and the rising incidence of urinary and fecal incontinence, along with other pelvic floor disorders, are expanding the addressable market for SNS devices. The growing awareness about the benefits of SNS therapy and favorable reimbursement policies in key markets are further driving adoption. Moreover, the expansion of healthcare access and infrastructure in emerging markets and the focus on expanding the clinical indications for SNS therapy are creating new opportunities for market growth, reinforcing the market’s potential.

Select Competitors (Total 23 Featured) -

• Abbott Laboratories, Inc.
• Avation Medical
• Axonics, Inc.
• BlueWind Medical
• Boston Scientific Corporation
• Dr. Langer Medical GmbH
• Inomed Medizintechnik GmbH
• Inspire Medical Systems, Inc.
• Laborie Medical Technologies, Corp
• Medtronic Plc

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.